NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LXRX stock has decreased by 12.3% and is now trading at $1.99. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Monday, April, 27th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.06. The biopharmaceutical company had revenue of $8 million for the quarter, compared to analyst estimates of $7.18 million. Lexicon Pharmaceuticals had a net margin of 26.59% and a return on equity of 125.61%. View Lexicon Pharmaceuticals' earnings history.

6 brokerages have issued twelve-month price targets for Lexicon Pharmaceuticals' stock. Their forecasts range from $2.10 to $9.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $4.53 in the next twelve months. This suggests a possible upside of 127.4% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals.

Press coverage about LXRX stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a news impact score of -1.9 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 10,920,000 shares, an increase of 8.5% from the June 15th total of 10,060,000 shares. Based on an average daily volume of 929,400 shares, the days-to-cover ratio is presently 11.7 days. Currently, 10.6% of the company's stock are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), Orexigen Therapeutics (OREX), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Micron Technology (MU).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%), Envestnet Asset Management Inc. (0.08%), Diversified Trust Co (0.02%) and Investors Financial Group LLC (0.01%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker. View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Wedbush Securities Inc., Diversified Trust Co, and Investors Financial Group LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker. View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $1.99.

Lexicon Pharmaceuticals has a market capitalization of $212.87 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.